Active Ingredient and Dosing
Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. The key difference is dosing: Ozempic is FDA-approved for type 2 diabetes at up to 2 mg weekly, while Wegovy targets weight loss at up to 2.4 mg weekly. Higher doses in Wegovy drive better weight loss outcomes in trials.[1]
Weight Loss Results from Clinical Trials
In the STEP 1 trial, Wegovy at 2.4 mg led to 14.9% average body weight loss over 68 weeks (vs. 2.4% on placebo).[2] Ozempic's SUSTAIN FORTE trial showed 15.4% loss at 2 mg over 40 weeks in diabetes patients, many with obesity, but real-world use often caps below 2.4 mg.[3] Head-to-head data is limited, but Wegovy's higher approved dose and obesity-focused trials suggest 2-5% greater loss than max-dose Ozempic for non-diabetics.[1][4]
Who Sees Better Results with Each
Wegovy outperforms for obesity without diabetes due to the 2.4 mg dose—patients lose 15-20% body weight sustained over 2 years in extensions.[2] Ozempic works well (10-15% loss) for diabetics with weight issues or off-label use, but insurance often restricts it to diabetes, limiting access to full dosing.[5] Factors like adherence, side effects, and starting BMI influence results; higher BMI favors Wegovy.[4]
Side Effects and Tolerability
Both cause nausea, vomiting, diarrhea, and constipation (20-40% of users), peaking early and fading. Wegovy's higher dose increases GI issues (dropout rate 7% vs. 3% placebo), but most tolerate it after titration.[2] Ozempic has similar rates at lower doses. Rare risks like pancreatitis or thyroid tumors apply to both; no clear edge in safety.[1][6]
Cost, Access, and Insurance Coverage
Wegovy lists at $1,349/month without insurance; Ozempic at $936. Off-label Ozempic for weight loss faces coverage denials, while Wegovy gets obesity-specific approval from many plans (e.g., Medicare Part D for some). Shortages hit both, but compounded semaglutide fills gaps at $200-400/month.[5][7]
Alternatives if Neither Fits
| Drug | Max Dose | Avg. Weight Loss | Key Use | Monthly Cost (No Ins.) |
|------|----------|------------------|---------|------------------------|
| Mounjaro (tirzepatide) | 15 mg | 20-22% (SURMOUNT-1) | Diabetes/obesity | $1,100 |
| Zepbound (tirzepatide) | 15 mg | 21% (SURMOUNT) | Obesity | $1,100 |
| Saxenda (liraglutide) | 3 mg daily | 8% | Obesity | $1,350 |
Tirzepatide options edge both for loss but cost more and have injection frequency differences.[8]
[1]: FDA Labels - Ozempic
[2]: NEJM - STEP 1 Trial
[3]: Diabetes Care - SUSTAIN FORTE
[4]: JAMA - Semaglutide Review
[5]: GoodRx Pricing Data
[6]: FDA Adverse Events
[7]: CMS Coverage Rules
[8]: NEJM - SURMOUNT-1